Outcome of allo-SCT for chronic myelomonocytic leukemia

Bone Marrow Transplantation

Volumn 43, Issue 8, 2009, Pages 659-661

  Ocheni, S ^a,b   Kroger N ^a   Zabelina, T ^a   Zander, A R ^a   Bacher, U ^a  

^a UNIVERSITY OF HAMBURG   (Germany)

^b UNIVERSITY OF NIGERIA   (Nigeria)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; BUSULFAN; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY; TREOSULFAN;

ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RELAPSE; CANCER SURVIVAL; CAUSE OF DEATH; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVING DONOR; MALE; MYELOABLATIVE CONDITIONING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; SEPSIS; SJOEGREN SYNDROME; SURVIVAL RATE; WHOLE BODY RADIATION;

ADULT; AGED; ALLELES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; MALE; MIDDLE AGED; RECURRENCE; RETROSPECTIVE STUDIES; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 67349253841     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2008.366     Document Type: Article

References (10)

1. Aul C, Giagounidis A, Germing U, Ganser A. Evaluating the prognosis of patients with myelodysplastic syndromes. Ann Hematol 2002; 81 485-497.
2. Platzbecker U, Mohr B, von Bonin M, Schetelig J, Ehninger G, Bornhauser M. Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus. Leukemia 2007; 21: 2384-2385.
3. Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L et al Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Ann Hematol 2004; 83: 498-503.
4. Deeg HJ, Shulman HM, Anderson JE, Bryant EM, Gooley TA, Slattery JT et al. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood 2000; 95: 1188-1194.
5. Kroger N, Zabelina T, Guardiola P, Runde V, Sierra J, Van Bienzen A et al. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2002; 118: 67-73.
6. Kroger N, Bornhauser M, Ehninger G, Schwerdtfeger R, Biersack H, Sayer HG et al. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol 2003; 82: 336-342.
7. Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006; 108: 1092-1099.
8. Elliott MA, Tefferi A, Hogan WJ, Letendre L, Gastineau DA, Ansell SM et al. Allogeneic stem cell transplantation and donor lymphocyte infusions for chronic myelomonocytic leukemia. Bone Marrow Transplant 2006; 37: 1003-1008.
9. Kerbauy DM, Chyou F, Gooley T, Sorror ML, Scott B, Pagel JM et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia. Biol Blood Marrow Transplant 2005; 11: 713-720.
10. Laport GG, Sandmaier BM, Storer BE, Scott BL, Stuart MJ, Lange T et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant 2008; 14: 246-255.